medical devices

Abbott maintains 54-year dividend streak with 10% EPS growth projected for 2026, despite near-term diagnostic headwinds and manufacturing challenges offsetting strategic acquisitions and FDA approvals.

DexCom benefits from GLP-1 drug expansion as CGM devices are increasingly prescribed together, unlocking significant untapped patient markets and complementary revenue opportunities.

Global anti-snoring devices market projected to nearly double to $3.36 billion by 2033, driven by obesity, health awareness, and technological advances.

Healthcare digital twins market expected to surge from $2.22B in 2025 to $69.67B by 2035, driven by AI integration and precision medicine adoption.

Neuromodulation device market expected to double to $16.1 billion by 2032, driven by rising neurological diseases, technological advances, and regulatory support.

Intuitive Surgical faces near-term headwinds but maintains strong long-term growth potential through its dominant robotic surgery platform, structural competitive advantages, and expanding market opportunities.

Medtronic offers defensive stability through 48 years of dividend increases, essential medical devices, and consistent profitability across economic cycles.

Intuitive Surgical posts double-digit growth in 2025 with 12% installed base expansion and 18% surgery increase, unaffected by GLP-1 drug market competition.

BioStem Technologies will present its perinatal tissue-based wound care platform at the TD Cowen Healthcare Conference on March 2, 2026, in Boston.

J&J plans to divest DePuy Synthes orthopedics unit valued at $20-28 billion. Private equity firms are negotiating potential acquisition bids as part of J&J's portfolio restructuring strategy.

Rigid endoscopes market to grow from $7.36B to $11.52B by 2033, driven by minimally invasive surgery demand and technological advances in imaging capabilities.

Axogen will present at three major healthcare conferences in March 2026, conducting investor meetings and showcasing its business case to institutional investors and analysts.

Danaher to acquire Masimo for $9.9 billion, expanding its healthcare technology portfolio. The deal represents a significant premium and major consolidation in medical devices.

Pulmonary artery catheter market projected to grow from $1.23B to $1.97B by 2035, driven by rising cardiovascular disease and expanding critical care infrastructure globally.